JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Reavill, C.
Right arrow Articles by Hagan, J. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Reavill, C.
Right arrow Articles by Hagan, J. J.

Vol. 294, Issue 3, 1154-1165, September 2000

Pharmacological Actions of a Novel, High-Affinity, and Selective Human Dopamine D3 Receptor Antagonist, SB-277011-A

Charlie Reavill , Stephen G. Taylor, Martyn D. Wood, Tracey Ashmeade, Nigel E. Austin, Kim Y. Avenell, Izzy Boyfield, Clive L. Branch, Jackie Cilia, Martyn C. Coldwell, Michael S. Hadley, A. Jackie Hunter, Phil Jeffrey, Frances Jewitt, Christopher N. Johnson, Declan N. C. Jones, Andrew D. Medhurst, Derek N. Middlemiss, David J. Nash, Graham J. Riley, Carol Routledge, Geoff Stemp, Kevin M. Thewlis, Brenda Trail, Antonio K. K. Vong and Jim J. Hagan

Departments of Neuroscience Research (C.R., S.G.T., M.D.W., T.A., K.Y.A., I.B., J.C., M.C.C., A.J.H., F.J., D.N.C.J., A.D.M., D.N.M., G.J.R., C.R., B.T., J.J.H.), Discovery Chemistry (C.L.B., M.S.H., C.N.J., D.J.N., G.S., K.M.T., A.K.K.V.), and Drug Metabolism and Pharmacokinetics (N.E.A., P.J.), SmithKline Beecham Pharmaceuticals, New Frontiers Science Park, Harlow, Essex, United Kingdom

SB-277011-A {trans-N-[4-[2-(6-cyano-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl]cyclohexyl]-4-quinolininecarboxamide}, is a brain-penetrant, high-affinity, and selective dopamine D3 receptor antagonist. Radioligand-binding experiments in Chinese hamster ovary (CHO) cells transfected with human dopamine D3 or D2 long (hD3, hD2) receptors showed SB-277011-A to have high affinity for the hD3 receptor (pKi = 7.95) with 100-fold selectivity over the hD2 receptor and over 66 other receptors, enzymes, and ion channels. Similar radioligand-binding data for SB-277011-A were obtained from CHO cells transfected with rat dopamine D3 or D2. In the microphysiometer functional assay, SB-277011-A antagonized quinpirole-induced increases in acidification in CHO cells overexpressing the hD3 receptor (pKb = 8.3) and was 80-fold selective over hD2 receptors. Central nervous system penetration studies showed that SB-277011-A readily entered the brain. In in vivo microdialysis studies, SB-277011-A (2.8 mg/kg p.o.) reversed the quinelorane-induced reduction of dopamine efflux in the nucleus accumbens but not striatum, a regional selectivity consistent with the distribution of the dopamine D3 receptor in rat brain. SB-277011-A (2-42.3 mg/kg p.o.) did not affect spontaneous locomotion, or stimulant-induced hyperlocomotion. SB-277011-A (4.1-42.2 mg/kg p.o.) did not reverse prepulse inhibition deficits in apomorphine- or quinpirole-treated rats, but did significantly reverse the prepulse inhibition deficit in isolation-reared rats at a dose of 3 mg/kg p.o. SB-277011-A (2.5-78.8 mg/kg p.o.) was noncataleptogenic and did not raise plasma prolactin levels. Thus, dopamine D3 receptor blockade produces few of the behavioral effects characteristic of nonselective dopamine receptor antagonists. The effect of SB-277011-A on isolation-induced prepulse inhibition deficit suggests that blockade of dopamine D3 receptors may benefit the treatment of schizophrenia.

0022-3565/00/2943-1154$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2000 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
J. M. Witkin, B. Levant, A. Zapata, R. Kaminski, and M. Gasior
The Dopamine D3/D2 Agonist (+)-PD-128,907 [(R-(+)-trans-3,4a,10b-Tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol)] Protects against Acute and Cocaine-Kindled Seizures in Mice: Further Evidence for the Involvement of D3 Receptors
J. Pharmacol. Exp. Ther., September 1, 2008; 326(3): 930 - 938.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. J. Millan, F. Loiseau, A. Dekeyne, A. Gobert, G. Flik, T. I. Cremers, J.-M. Rivet, D. Sicard, R. Billiras, and M. Brocco
S33138 (N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1] benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenyl-acetamide), a Preferential Dopamine D3 versus D2 Receptor Antagonist and Potential Antipsychotic Agent: III. Actions in Models of Therapeutic Activity and Induction of Side Effects
J. Pharmacol. Exp. Ther., March 1, 2008; 324(3): 1212 - 1226.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. J. Millan, C. M. la Cour, F. Novi, R. Maggio, V. Audinot, A. Newman-Tancredi, D. Cussac, V. Pasteau, J.-A. Boutin, T. Dubuffet, et al.
S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], A Preferential Dopamine D3 versus D2 Receptor Antagonist and Potential Antipsychotic Agent: I. Receptor-Binding Profile and Functional Actions at G-Protein-Coupled Receptors
J. Pharmacol. Exp. Ther., February 1, 2008; 324(2): 587 - 599.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. J. Millan, P. Svenningsson, C. R. Ashby Jr., M. Hill, M. Egeland, A. Dekeyne, M. Brocco, B. Di Cara, F. Lejeune, N. Thomasson, et al.
S33138 [N-[4-[2-[(3aS,9bR)-8-Cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a Preferential Dopamine D3 versus D2 Receptor Antagonist and Potential Antipsychotic Agent. II. A Neurochemical, Electrophysiological and Behavioral Characterization in Vivo
J. Pharmacol. Exp. Ther., February 1, 2008; 324(2): 600 - 611.
[Abstract] [Full Text] [PDF]

Home page
 J PsychopharmacolHome page
J. Cilia, P. Hatcher, C. Reavill, and D. N. C. Jones
({+/-}) Ketamine-induced prepulse inhibition deficits of an acoustic startle response in rats are not reversed by antipsychotics
J Psychopharmacol, May 1, 2007; 21(3): 302 - 311.
[Abstract] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
J. L. Martelle, R. Claytor, J. T. Ross, B. A. Reboussin, A. H. Newman, and M. A. Nader
Effects of Two Novel D3-Selective Compounds, NGB 2904 [N-(4-(4-(2,3-Dichlorophenyl)piperazin-1-yl)butyl)-9H-fluorene-2-carboxamide] and CJB 090 [N-(4-(4-(2,3-Dichlorophenyl)piperazin-1-yl)butyl)-4-(pyridin-2-yl)benzamide], on the Reinforcing and Discriminative Stimulus Effects of Cocaine in Rhesus Monkeys
J. Pharmacol. Exp. Ther., May 1, 2007; 321(2): 573 - 582.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
I. Gyertyan, B. Kiss, K. Gal, I. Laszlovszky, A. Horvath, L. I. Gemesi, K. Saghy, G. Pasztor, M. Zajer, M. Kapas, et al.
Effects of RGH-237 [N-{4-[4-(3-Aminocarbonyl-phenyl)-piperazin-1-yl]-butyl}-4-bromo-benzamide], an Orally Active, Selective Dopamine D3 Receptor Partial Agonist in Animal Models of Cocaine Abuse
J. Pharmacol. Exp. Ther., March 1, 2007; 320(3): 1268 - 1278.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
A. Bespalov, A.-L. Jongen-Relo, M. van Gaalen, S. Harich, H. Schoemaker, and G. Gross
Habituation Deficits Induced by Metabotropic Glutamate Receptors 2/3 Receptor Blockade in Mice: Reversal by Antipsychotic Drugs
J. Pharmacol. Exp. Ther., February 1, 2007; 320(2): 944 - 950.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
V. Vengeliene, F. Leonardi-Essmann, S. Perreau-Lenz, P. Gebicke-Haerter, K. Drescher, G. Gross, and R. Spanagel
The dopamine D3 receptor plays an essential role in alcohol-seeking and relapse
FASEB J, November 1, 2006; 20(13): 2223 - 2233.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
G. T. Collins, J. M. Witkin, A. H. Newman, K. A. Svensson, P. Grundt, J. Cao, and J. H. Woods
Dopamine Agonist-Induced Yawning in Rats: A Dopamine D3 Receptor-Mediated Behavior
J. Pharmacol. Exp. Ther., July 1, 2005; 314(1): 310 - 319.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
S. R. Vorel, C. R. Ashby Jr, M. Paul, X. Liu, R. Hayes, J. J. Hagan, D. N. Middlemiss, G. Stemp, and E. L. Gardner
Dopamine D3 Receptor Antagonism Inhibits Cocaine-Seeking and Cocaine-Enhanced Brain Reward in Rats
J. Neurosci., November 1, 2002; 22(21): 9595 - 9603.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. PsychiatryHome page
H. M. JONES and L. S. PILOWSKY
Dopamine and antipsychotic drug action revisited
The British Journal of Psychiatry, October 1, 2002; 181(4): 271 - 275.
[Full Text] [PDF]

Home page
 J. Neurosci.Home page
S. B. Caine, S. S. Negus, N. K. Mello, S. Patel, L. Bristow, J. Kulagowski, D. Vallone, A. Saiardi, and E. Borrelli
Role of Dopamine D2-like Receptors in Cocaine Self-Administration: Studies with D2 Receptor Mutant Mice and Novel D2 Receptor Antagonists
J. Neurosci., April 1, 2002; 22(7): 2977 - 2988.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
C. R. Ashby Jr., Y. Minabe, G. Stemp, J. J. Hagan, and D. N. Middlemiss
Acute and Chronic Administration of the Selective D3 Receptor Antagonist SB-277011-A Alters Activity of Midbrain Dopamine Neurons in Rats: An In Vivo Electrophysiological Study
J. Pharmacol. Exp. Ther., September 1, 2000; 294(3): 1166 - 1174.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2000 by the American Society for Pharmacology and Experimental Therapeutics.